The antimicrobial activities of telavancin and six comparators were evaluated against 460 isolates of anaerobic bacteria. Telavancin demonstrated excellent activity against gram-positive anaerobes (MIC 90 , 2 g/ml) and was the most potent agent tested against Clostridium difficile (MIC 90 , 0.25 g/ml). As expected, gram-negative isolates were not inhibited by telavancin.
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Telavancin is an investigational lipoglycopeptide (9) with activity against clinically important gram-positive pathogens, including methicillin (meticillin)-resistant Staphylococcus aureus (5, 7, 17) , as well as vancomycin-intermediate S. aureus and heteroresistant vancomycin-intermediate S. aureus (10) . Mechanistically, telavancin operates by a dual mechanism that includes inhibition of cell wall synthesis and disruption of the bacterial membrane function (6) . Telavancin is currently under regulatory review as a once-daily treatment for complicated skin and skin structure infections and hospital-acquired pneumonia caused by gram-positive bacteria (16, (20) (21) . Mixed infections due to aerobic and anaerobic bacteria are diagnosed frequently in patients with deep-seated soft tissue infections (1) , including diabetic patients with chronic wounds of the lower extremities (11) .
Since glycopeptides are not absorbed to any appreciable extent following peroral administration (22) , an additional indication for which telavancin may have utility is the treatment of intestinal infections such as those caused by Clostridium difficile. Therefore, we compared the in vitro activity of telavancin with those of ampicillin-sulbactam, clindamycin, daptomycin, linezolid, metronidazole, and vancomycin against a collection of 460 anaerobic gram-positive and gram-negative isolates. The bacteria included in this study were isolated during the previous 3 to 5 years at the Wadsworth Anaerobe Laboratory, VA Greater Los Angeles Healthcare System, Los Angeles, CA, according to the procedures outlined in the Wadsworth-KTL anaerobic manual (8) . Two-thirds of the isolates were from clinical infections (19% from soft tissue infections, 12% from peritoneal fluid, 15% from intra-abdominal abscesses, 6% from blood cultures, and the rest from a variety of specimens, including lung tissue, pleural fluid, and pelvic abscesses), and one-third was recovered from stool samples. Biochemical and other phenotypic criteria as well as 16S rRNA sequencing were used to establish the identity of the individual bacterial isolates (8, 19) .
Reference strains of Bacteroides fragilis (ATCC 25285), Bacteroides thetaiotaomicron (ATCC 29741), and Eggerthella lenta (ATCC 43055) were used as quality control strains in each test. Antimicrobial agents were obtained in the form of lyophilized powders from manufacturers as follows: amoxicillin (amoxicilline), clindamycin, metronidazole, and vancomycin from Sigma (St. Louis, MO); daptomycin from Cubist Pharmaceuticals (Lexington, MA); sodium sulbactam and linezolid from Pfizer (Groton, CT); and telavancin from Theravance, Inc. (South San Francisco, CA). Antimicrobial concentration ranges were selected to encompass the peak and trough plasma concentrations reported in humans (2, 12-13, 15, 18, 22) .
Dimethyl sulfoxide was used to facilitate the solubilization of telavancin at concentrations of Ն64 g/ml. MICs were determined by the NCCLS-approved Wadsworth agar dilution technique (14) , using an inoculum of 10 5 CFU and Brucella baselaked blood agar (Anaerobe Systems, Morgan Hill, CA) that was supplemented with pyruvic acid (1% final concentration) for the growth of Bilophila wadsworthia and formic and fumaric acids (0.3%/0.3%) for Sutterella wadsworthensis. For daptomycin, the basal medium was supplemented with 50 mg/ml calcium chloride. Plates were incubated at 37°C for 48 h in an anaerobic chamber (Anaerobe Systems, Morgan Hill, CA). Triphenyltetrazolium chloride was used to aid the interpretation of the B. wadsworthia growth endpoints (8) . MICs were read as the lowest concentration of antimicrobial resulting in no growth or a marked change in the appearance of growth compared to that of the control plate.
The concentrations that were required to inhibit the growth of 50% (MIC 50 ) and 90% (MIC 90 ) of strains and the corresponding MIC ranges are listed in Table 1 . Against the 329 gram-positive anaerobes, telavancin demonstrated excellent activity (MIC 90 , 2 g/ml; geometric mean, 0.28 g/ml), which was equaled only by ampicillin-sulbactam (MIC 90 , 2 g/ml; geometric mean, 0.47 g/ml). Within the Clostridium group, telavancin was the most potent of the seven agents tested against C. difficile (MIC 90 , 0.25 g/ml), Clostridium ramosum (MIC 90 , 0.25 g/ml), Clostridium subterminale (MIC 90 , Յ0.12 g/ml), and a group of 71 Clostridium isolates of miscellaneous species (MIC 90 , 0.25 g/ml). Elevated telavancin MICs were observed against Clostridium bolteae and Clostridium clostridioforme (MIC 90 , 8 g/ml). The in vitro susceptibility data for Holdemania filiformis, an uncommon non-spore-forming, anaerobic, gram-positive bacillus, was the only gram-positive anaerobe for which telavancin had elevated MICs. The three H. filiformis strains tested had MICs of 32 g/ml, 64 g/ml, and 0.25 g/ml. The corresponding vancomycin MICs for these strains were 64 g/ml, 64 g/ml, and 32 g/ml, respectively. As expected, the anaerobic gram-negative bacilli studied were not susceptible to telavancin (MIC 50 , Ͼ64 g/ml; geometric mean, 49 g/ml), daptomycin (MIC 50 , Ͼ128 g/ml), or vancomycin (MIC 50 , 128 g/ml). Telavancin had limited activity against Prevotella species (MIC 50 , 8 g/ml). Overall, metronidazole was the most active agent against the gramnegative anaerobes tested (MIC 50 , 0.5 g/ml; MIC 90 , 2 g/ml). The relatively poor activity against gram-negative anaerobic bacteria, which constitute the bulk of indigenous bowel flora, should make telavancin an excellent candidate for therapy of C. difficile intestinal infections and other pathology, such as autism, in which certain intestinal clostridia may play a role (3). In summary, the in vitro activities reported in this study support further development of telavancin for the treatment of infections involving gram-positive anaerobes.
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Editorial support was provided by I. Stoilov, Envision Scientific Solutions. a C. bartlettii (7), C. beijerinckii (1), C. bifermentans (6), C. butyricum (5), C. celerecrescens (4), C. disporicum (9), C. glycolicum (9), "C. hypermegas" (1), C. leptum (1), C. orbiscindens (2), C. paraputrificum (7), C. scindens (2), C. sordellii (5), C. spiroforme (1), C. sporogenes (6) , C. sporosphaeroides (1), C. tertium (1), Clostridium species not identified to the species level (3) .
b Actinomyces naeslundii (1), Bifidobacterium adolescentis (7), Bifidobacterium bifidum (1), Bifidobacterium breve (2), Bifidobacterium dentium (3), Bifidobacterium infantis (2), Bifidobacterium longum (2), Bifidobacterium pseudolongum (6) e S. anginosus (7), S. constellatus (9), S. intermedius (9) . These organisms are listed among the anaerobic gram-positive species because they are often microaerophilic, and anaerobic conditions facilitate their recovery.
f P. distasonis (5), P. merdae (5 
